To explain the pathophysiological significance of endogenous atrial natriuretic polypeptide (ANP) in the development of hypertension, we examined the effect of chronic, repetitive administrations of MAb raised against a-rat ANP in two rat models of hypertension, spontaneously hypertensive rats of the stroke prone substrain (SHR-SP), and deoxycorticosterone ac- 
Introduction
The pioneering discovery that atrial extracts possess potent diuretic and natriuretic activities (1) was followed by subse-quent identifications of atrial natriuretic polypeptide (ANP)' in human and rat atria (2) (3) (4) . It has been recognized that ANP is synthesized in the cardiac myocyte and secreted into the blood stream through the coronary sinus (5) , in response to extracellular volume expansion (6) (7) (8) via the stretch-secretion coupling mechanism (3, 4) . In many cardiovascular and endocrine disorders associated with elevated cardiac filling pressure, the plasma ANP level is increased (5, (9) (10) (11) .
Exogenously administered ANP induces not only diuresis and natriuresis, but also relaxation ofvascular smooth muscles and inhibition of renin, aldosterone, and vasopressin release in animals and in humans (3, 4, 8, 1 1) . Until now, however, the information on the pathophysiological significance of circulating ANP has been scarce. Whether ANP functions at circulatory levels encountered under physiological perturbations or pathophysiological conditions has not been resolved, mainly because of a lack of a specific inhibitor for ANP.
Several laboratories, including ours, have reported that plasma ANP levels are elevated both in patients with essential hypertension and secondary hypertension due to hyperaldosteronism or renal hypertension (12, 13) , and in several hypertensive animals, including spontaneously hypertensive rats (SHR) and its substrain, SHR-stroke prone (SHR-SP) (14) (15) (16) , and deoxycorticosterone acetate (DOCA)-salt rats (17, 18) . In addition, we have recently explained augmented gene expression of the ANP gene in the ventricle, as well as in the atrium in SHR and SHR-SP at the stage ofhypertension and ventricular hypertrophy (19, 20) . These findings suggest that augmented secretion of ANP plays a compensatory role in the maintenance of blood pressure. In addition, an infusion of ANP (5-100 ng/kg per min) for a couple of days to a week caused a reduction in blood pressure in SHR; rats with onekidney, one-clip or two-kidney, one-clip renal hypertension; or angiotensin II-or norepinephrine-infused rats (21, 22) , without consistent changes in urine volume or urinary excretion of sodium. In patients with essential hypertension, a bolus injection (50-100 ,ug) or an infusion (1 ug/min) of relatively high doses of ANP caused rises in urine volume and sodium excretion and a fall in arterial pressure (23, 24) . However, the extent to which increased levels of endogenous ANP participate in the modulation of hypertension has not been clarified yet.
is specific for a-human ANP (a-hANP) but not for a-rat ANP (a-rANP), whereas KY-ANP-II recognizes a-hANP and arANP equally. The MAb is devoid ofseveral drawbacks inherent to polyclonal antisera, such as epitope heterogeneity or the contamination with irrelevant antibodies raised against other ligands. In this study, we used these two MAbs against ANP to examine the effect of passive immunization in two rat models of hypertension, SHR-SP and DOCA-salt rats, during the course ofthe development ofhypertension, to clarify the possible pathophysiological significance of endogenous ANP in the evolution of hypertension.
Methods
Preparation and administration ofMAb against ANP. The preparation of MAbs against ANP was performed by standard methods as described previously in detail (25, 26) . In these experiments, we used two MAbs against ANP: one was an MAb directed towards the NH2 terminus of a-ANP, a common portion of the amino acid sequence of a-rANP and a-hANP, which was named KY-ANP-II (MAb[KY-ANP-II]) (26) . The RIA for this antibody MAb[KY-ANP-II] showed equal cross-reactivities with a-rANP and a-hANP, but NH2-terminally deleted forms of a-ANP, that is, a-rANP , a-rANP , ahANP , and a-hANP exhibited cross-reactivities of < 0.01% on a molar basis (Table I) a-hANP 100 100 a-rANP(cardionatrin) 100 0.9 a-hANP 0.2 100 a-rANP 0.2 0.9 a-hANP <0.01 100 a-rANP (ANF IV, auriculin B) <0.01 0.9 a-hANP <0.001 100 a-rANP (atriopeptin III) <0.001 0.9 a-hANP <0.001 100 a-rANP facturing Co., Tokyo, Japan). Urinary concentrations of sodium and potassium were determined by the ion electrode method (Hitachi autoanalyzer model 736; Hitachi Medical Co., Tokyo, Japan). Determination ofplasma ANP levels, cGMP levels, and other biochemical data. Blood (250 Ml) was obtained through the venous catheter from conscious, unrestrained rats as previously described (7, 14) .
Plasma ANP concentrations in rats were determined by the RIA with a rabbit polyclonal antiserum raised against a COOH-terminal fragment of a-ANP, a-ANP [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , as described previously in details (31) . The RIA can equally recognize a-ANP [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , a-rANP, a-hANP, arANP , a-rANP , and a-rANP . The lowest detectable concentration of ANP was 1 pg/tube and the amount of 50% binding inhibition (IC50) was 25 pg/tube. Plasma ANP-like immunoreactivity was determined with 25 Ml of rat plasma without extraction (7, 14, 17) .
Plasma cGMP concentrations were determined with a commercially available RIA kit (YAMASA cyclic GMP assay kit; Yamasa Shoyu Co., Chiba, Japan) according to the method of Steiner et al. (32) . Serum sodium, potassium, creatinine, and blood urea nitrogen were determined by the standard analytical techniques. were performed nine times: just after the determination of blood pressure before DOCA and 1% NaCI administration, and then, weekly for the next 8 wk. The blood pressure of the rats in the three groups was measured at 2-wk intervals, each time the day after the administration ofascites containing MAbs. 8 wk after the start ofthe treatment, urine volume and urinary excretions of sodium and potassium were determined in three groups of rats, using the metabolism cage by offering rats in all three groups 1% NaCI to drink. After that, blood sampling was performed while rats were in a conscious, unrestrained state through a venous catheter as described above. In experiment 6-2, 17 male Slc: Wistar rats (320±2 g) from the same source in experiment 2 received the same treatment of DOCA and 1% NaCl administration, and were divided into two groups. DOCA-salt rats in group 6-2A (n = 9) received weekly intravenous injections of 100 M1 ascitic fluid containing control MAb[KY-ANP-I], whereas those in group 6-2B (n = 8) did not receive any injection of MAb-containing ascites. Blood pressure of each DOCA-salt rat was measured at intervals of 2 wk, as described in experiment 2 until 6 wk after the start of the treatment.
Statistical analysis. All values are expressed as mean±SEM. Analysis of variance of repeated measures, with subsequent Duncan's test, was used to determine significant changes during time-dependent multiple observations (33) . Linear regression analysis was performed with the method of least squares. The statistical significance was defined as P < 0.05. Values are means±SEM of the 3-d observation period. Before, before treatment, when rats were 6 wk old. After, after treatment, when rats were 10 wk old.
Results
Before the repetitive administrations of MAb, blood pressure of SHR-SP in groups lA and lB (n = 16, 148±1 mmHg) was significantly higher than that of WKY in groups IC and ID (n = 16, 104±2 mmHg) (P < 0.01) and this difference was maintained throughout the observation period, with the time-dependent, significant increase of blood pressure of both rat strains. 1 wk after the start of the administration of MAb-containing ascites (two injections), SHR-SP in group IA, which received MAb[KY-ANP-II] with high affinity for a-rANP, exhibited significantly higher blood pressure (182±2 mmHg) than that of SHR-SP in group 1B (162±2 mmHg, P < 0.01), which received MAb[KY-ANP-I] with low affinity for arANP, though blood pressure before the treatment was not significantly different in the two groups (148±2 mmHg for group IA and 148±1 mmHg for group IB). The trend of significantly higher blood pressure of SHR-SP in group IA compared with group lB persisted throughout the observation period ofthe following 2 wk. In contrast to SHR-SP, there was no appreciable difference in blood pressure throughout the obser- Effects of the chronic administration of two MAbs against ANP on urine volume and urinary electrolyte excretions are shown in Table II . No significant differences in any renal excretory parameters were observed between the two rat strains or the two treatments. Experiment 2. Fig. 2 illustrates the evolution of hypertension in DOCA-salt rats treated with two different MAb against ANP and control rats without the administration of MAbs. Blood pressure of the rats in three groups did not significantly differ before the treatment (139±7 mmHg in group 2A, 133±6 mmHg in group 2B, and 139±3 mmHg in group 2C). In the rats in group 2C, which received weekly vehicle corn oil injections and were offered tap water to drink, blood pressure did not significantly alter throughout the observation period. DOCA and 1% NaCl administration caused a significant and progressive rise in blood pressure of the rats in both groups 2A and 2B. Blood pressure of DOCA-salt rats in group 2A (173±5 mmHg) was significantly higher than that of untreated control rats in group 2C (137±6 mmHg) as early as 2 wk after the start of the treatment (P < 0.01), and blood pressure of DOCA-salt rats in group 2B became significantly higher 4 wk after the start of the treatment (160±4 mmHg) than that of control rats (136±5 mmHg, P < 0.01).
As with the case in the development of hypertension in SHR-SP, the chronic repetitive administrations of the MAb against a-rANP accelerated the progression of blood pressure elevation in DOCA-salt rats. Blood pressure of DOCA-salt rats in group 2A treated with MAb[KY-ANP-II] 4 wk after the start of the administration (180±5 mmHg) was significantly higher than that in group 2B treated with MAb[KY-ANP-I] (160±4 mmHg, P < 0.05) and the significant difference persisted for the next 4 wk. Table III summarizes effects of the chronic administration of two MAbs against ANP on urine volume and urinary electrolyte excretions of DOCA-salt rats after the completion of nine administrations of MAbs. DOCA-salt rats in group 2B excreted five times volume of urine (P < 0.01) and 3.7 times more sodium (P < 0.01) than those ofcontrol rats in group 2C, although potassium excretions were comparable in these two groups. The chronic repetitive administrations of MAb[KY-ANP-II] attenuated diuresis and natriuresis induced by DOCA and 1% NaCl administration. Urine volume and urinary excretion of sodium of DOCA-salt rats treated with MAb[KY-ANP-II] in group 2A were significantly lower than those of DOCA-salt rats in group 2B (P < 0.05, respectively). As shown in Table III , however, there was no significant difference in serum sodium, potassium, creatinine or blood urea nitrogen level between group 2A and group 2B. Serum sodium levels in DOCA-salt rats both in groups 2A and 2B were significantly higher than that in control rats in group 2C, and conversely, serum potassium levels in DOCA-salt rats both in groups 2A and 2B were significantly lower than that in control rats in group 2C.
Plasma cyclic GMP levels of the rats in three groups after the completion of nine administrations of MAb against ANP are shown in Table IV. The plasma cyclic GMP level of DOCA-salt rats in group 2B was significantly elevated compared with that of untreated control rats in group 2C. The plasma cyclic GMP level of DOCA-salt rats in group 2A treated with MAb[KY-ANP-II] was significantly lower than that of DOCA-salt rats in group 2B (P < 0.05) and was suppressed to the level of control rats in group 2C. In the same series of the radiobinding assay, the specific binding of '251I-a-hANP with serum at the same dilution ob- Fig. 3 . Experiment 4. A bolus injection of 5 Mg of synthetic ahANP produced a prompt and significant increase of the plasma cGMP level in rats in group 4-1A (Fig. 4 A) . The plasma ANP level rose up to 2,240±280 pg/ml 5 min after the administration, and administered a-hANP rapidly disappeared from the rat circulation (Fig. 4 C) . There was a significant positive correlation between plasma ANP levels and plasma cyclic GMP levels (r = 0.91, P < 0.01).
The pretreatment with 100 ul ascitic fluid containing
MAb[KY-ANP-II] significantly attenuated a-hANP-induced increase ofthe plasma cGMP level, as depicted in Fig. 4A . The plasma cyclic GMP level of rats in group 4-1B 5 min after the administration of a-hANP (37±6 pmol/ml) was significantly lower than the corresponding value in group 4-lA (77±12 pmol/ml, P < 0.01). The intravenous bolus injection of 5 ,ug AVP caused a massive rise in the plasma ANP level, which persisted until 20 min after the administration, as previously reported (7, 35) (Fig. 4 D) . After the administration of 5 ,ug AVP, a parallel rise of the plasma cyclic GMP level was observed in rats in group 4-2A, as shown in Fig. 4 B. There was a significant positive correlation between plasma ANP levels and plasma cGMP levels after the AVP administration (r = 0.70, P < 0.01).
The pretreatment with 100 Al ascitic fluid containing MAb[KY-ANP-II] significantly suppressed the increase of the plasma cGMP level associated with the AVP-induced elevation of endogenous ANP level (Fig. 4B) . The plasma cGMP levels in rats in group 4-2B 5 min (44±6 pmol/ml) and 10 min (58±6 pmol/ml) after the AVP administration were significantly lower than those in rats in group 4-2A (128±13 pmol/ ml, P < 0.01; 140+8 pmol/ml, P < 0.01, respectively).
Experiment 5. The mean basal plasma ANP level of SHR-SP at the age of 9 wk was 303±51 pg/ml (n = 9), which was significantly higher than that of age-matched WKY, 143±21 pg/ml (n = 9) (P < 0.05). The simultaneously determined plasma cGMP levels were 11.3±0.7 pmol/ml for SHR-SP and 7.5±0.4 pmol/ml for WKY. The difference of plasma cyclic GMP levels in the two rat strains was significant (P < 0.01), and there was a significant positive correlation between plasma ANP levels and plasma cyclic GMP levels (r = 0.70, P < 0.01). pmol/ml) were significantly higher than those ofWKY (n = 4) (7.6±0.5 pmol/ml, P < 0.01; 7.6±0.8 pmol/ml, P < 0.05, respectively). The Blood pressure of DOCA-salt rats in group 6-2A treated with MAb[KY-ANP-IJ was 139±1 mmHg (before treatment), 152±2 mmHg (2 wk) 156±10 mmHg (4 wk) and 167±6 mmHg (6 wk after the start of the treatment). Blood pressure of DOCA-salt rats in group 6-2B without any treatment was 139±3 mmHg (before treatment), 150±9 mmHg (2 wk), 158±4 mmHg (4 wk) and 170±5 mmHg (6 wk after the start of the treatment). There was, therefore, no significant difference in the evolution of hypertension between DOCA-salt rats without any injection of ANP MAb and those treated with MAb[KY-ANP-I].
Discussion
To explain the pathophysiological role ofaugmented secretion of ANP in hypertension, we studied the effects of chronic repetitive administrations of MAbs against ANP in two animal models of hypertension: SHR-SP and DOCA-salt rats. This study clearly demonstrates the acceleration of the development of hypertension by the specific blockade of increased circulating ANP in both hypertensive rats.
The ability of our MAb against a-rANP (MAb[KY-ANP-II]) to block the biological activities ofcirculating a-rANP was verified in experiment 4. The pretreatment of MAb[KY-ANP-II] significantly suppressed the increase ofplasma cGMP levels associated with the increase of plasma ANP levels by the administration of exogenous a-hANP (experiment 4-1) or by the administration of synthetic AVP (experiment , which stimulated endogenous ANP secretion from the heart, as previously reported (7, 35). The intravenous administration of MAb[KY-ANP-I] with low affinity for a-rANP, which we used as a control in this study, elicited no effect on the increase of the plasma cGMP level after the administration of AVP (data not shown). (36) . In humans and rats, the intravenous administration ofANP was reported to elevate the plasma cGMP level (37) . In this study, after the administrations of synthetic a-hANP and AVP, there existed significant positive correlations between plasma ANP levels and plasma cGMP levels. In experiment 5, we further observed a significant positive correlation between basal plasma ANP levels and plasma cyclic GMP levels in SHR-SP and WKY. It was also reported that various ANP fragments of different potencies exert their biological activities that correlate with ANP-induced cGMP increases (37 interpreted as the inhibition of vasodilating action of endogenous ANP at the enhanced level, which resulted in the aggravation of hypertension in our hypertensive rats. Volume overload is considered to be one of the mechanisms in the manifestation of hypertension in DOCA-salt rats. DOCA administration causes increased sodium reabsorption in the kidney and induces salt appetite in rats (30). In this study, DOCA-salt rats showed significantly higher serum sodium concentration with a reciprocal decrease of serum potassium concentration with larger intake of 1% NaCl solution, compared with control rats. Diuresis and natriuresis induced by DOCA and 1% NaCl administration were significantly reduced by the administration of MAb[KY-ANP-II] in this study. Serum creatinine and blood urea nitrogen levels of DOCA-salt rats in both groups 2A and 2B were almost the same and within the normal range. Impaired diuresis and natriuresis in DOCA-salt rats in group 2A thus were not considered to be ascribed to renal dysfunction caused by a non-specific effect of MAb[KY-ANP-II] or by sustained higher blood pressure observed in DOCA-salt rats treated with MAb[KY-ANP-II]. There are several reports that suggest the role ofANP in diuresis and natriuresis after acute hypervolemia in rats (46) . Recently, Hirth et al. demonstrated blunted diuresis and natriuresis after volume expansion by ANP MAb (47) . Our results of the attenuation of exaggerated diuresis and natriuresis in DOCA-salt rats by ANP MAb further support the role of increased plasma levels of ANP in accelerating diuresis and natriuresis in volume-overloaded state. Insufficient diuresis and natriuresis and, as a consequence, possibly more expanded circulatory volume in DOCA-salt rats treated with MAb[KY-ANP-II] might be associated with the acceleration of hypertension in these rats, though we have not measured extracellular fluid volume in the present study.
In experiment 1, we could observe no significant difference in urine volume or urinary excretion of sodium in SHR-SP and WKY, though some reports show the pressure-induced diuresis and natriuresis in SHR (21) . The reason for such disparity is not clear at present, but it may result from substrain differences or animal ages. During the developmental phase of hypertension, plasma volume and blood volume of SHR-SP are reported to be reduced compared with age-matched WKY (48) . Lack of influence of MAb[KY-ANP-II] on urine volume or urinary excretion of sodium in SHR-SP might be, therefore, due to contracted or, at least, not increased body fluid volume in SHR-SP. The enhancing effect ofANP MAb on blood pressure in SHR-SP observed in this study, therefore, may be mainly attributed to the further increase of peripheral resistance, which is reported to be elevated in SHR (49), by the possible inhibition ofvasodilating actions of endogenous ANP with ANP MAb.
After the submission of our manuscript, Needleman's group reported the effect of autoimmunization with ANP in SHR on the development of hypertension (50) . They failed to detect any alteration in the increase of blood pressure of autoimmune SHR sensitized against ANP, compared with nonimmune SHR. The exact cause of the difference between our results and theirs is not clear at present. It may be accounted for by the difference of SHR substrain or by the difference in the experimental protocol. As we previously reported (14, 19, 20) , biosynthesis and secretion of ANP in SHR-SP with a severer form of hypertension are more augmented than those in SHR. Therefore, we adopted SHR-SP in our experiment. It is also possible that the different experimental procedures might have resulted in the different results. Because they immunized SHR with ANP during their observation period to produce ANP autoantibodies, it was not clear whether the sufficient titer of the antibodies in plasma was maintained in the developmental phase of hypertension. In addition, because their ANP autoantibodies were polyclonal, their binding affinity for ANP and recognition site must have been heterogenous. In the present study, we repetitively administered the MAb against ANP, which was homogenous in epitope recognition and binding affinity and demonstrated to antagonize the biological activity of ANP, before and during the occurrence of hypertension. We also confirmed the significant suppression of the enhanced plasma levels of cGMP in our hypertensive rats by ANP MAb.
In conclusion, this study demonstrated that chronic repetitive administrations of the MAb against a-rANP accelerated the development of hypertension in two animal models of hypertension, SHR-SP and DOCA-salt rats. These findings support the compensatory role ofaugmented secretion ofANP in these hypertensive animals and suggest that increased secretion of ANP could represent one of the antihypertensive deterrent mechanisms.
